BMS-986504 for MTAP-deficient relapsed mesothelioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called BMS-986504 in people whose mesothelioma has come back after treatment and whose tumors lack a protein called MTAP. The drug may help by blocking a specific pathway that these cancer cells need to grow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of mesothelioma (in the pleura or elsewhere).
- Your disease has grown after at least one earlier treatment (like chemotherapy).
- You are 18 or older and generally able to carry out daily activities (ECOG 0–1).
- No active brain metastases that are growing or causing symptoms.
- Your tumor must be 'MTAP-deficient' – a lab test will confirm this.
- You must be willing to give a fresh tissue sample and blood samples for the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
This trial tests a new drug called BMS-986504 alongside standard treatments for certain advanced cancers (mesothelioma, stomach/esophageal cancer, or bladder cancer). The drug targets a specific genetic change (MTAP deletion) that may make cancer cells more vulnerable to treatment. Joining could help you access a new therapy, but it may not be suitable for everyone.
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
This trial tests a new drug, BMS-986504, in people with pancreatic cancer that has a specific genetic change called MTAP deletion. The study aims to see if this drug can help shrink or control the tumor.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.